全球危重肢體缺血治療市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

全球危重肢體缺血治療市場需求預計將從 2022 年的 50.5 億美元增至 2030 年的近 132.7 億美元，2023-2030 年研究期間年複合成長率為 11.33%。

嚴重肢體缺血是指 PAD（外周動脈疾病）的晚期階段。嚴重肢體缺血的治療通常包括預防血栓、降低血壓和降低膽固醇的藥物，或使用其中一根靜脈或合成替代物修復或更換動脈的手術。此外，有時還可能包括血管內治療。所有這些方法都旨在恢復患者手腳的正常血流，以減少需要截肢的機會。

市場動態：

推動嚴重肢體缺血市場的主要因素包括嚴重肢體缺血患病率的成長和豐富的產品線。此外，採用有前景的治療策略（例如最佳血運重建）也有望擴大全球危重肢體缺血治療市場。血管內和最佳血運重建技術的進步是關鍵的肢體缺血治療市場趨勢。此外，改善血運重建結果並重點減少缺血相關心血管危險因素的需求為行業參與者提供了良好的機會。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球嚴重肢體缺血治療市場的各個細分市場進行了包容性評估。嚴重肢體缺血治療行業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲的嚴重肢體缺血治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。危重肢體缺血治療市場的主要參與者包括波士頓科學公司、Cesca Therapeutics Inc.、Abbott Laboratories、Pluristem Therapeutics Inc.、Rexgenero Ltd、LimFlow SA、Micro Medical Solutions、心血管系統公司。競爭格局，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第一章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法論
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：嚴重肢體缺血治療 - 行業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 行業動態
• 波特五力分析
• 市場吸引力分析
  • 按處理方式進行的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷管道發展趨勢

第 5 章：COVID-19 爆發的影響分析

第 6 章：全球危重肢體缺血治療市場分析：按治療分類

• 按治療概述
• 歷史和預測數據
• 按治療分析
• 藥物（抗血小板藥、抗高血壓藥、降脂藥、抗血栓藥、其他）
• 器械（栓塞防護裝置、外周擴張系統、球囊擴張器、血管支架）

第 7 章：全球危重肢體缺血治療市場分析：按地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概述、歷史和預測銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家/地區銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概述、歷史和預測銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家/地區銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概述、歷史和預測銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區國家/地區銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳大利亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概述、歷史和預測銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家/地區銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概述、歷史和預測銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 8 章：嚴重肢體缺血治療公司的競爭格局

• 嚴重肢體缺血治療市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 9 章：公司簡介

• 頂級公司市場佔有率分析
• 市場集中度
• Boston Scientific Corporation
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Cesca Therapeutics Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Abbott Laboratories
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Pluristem Therapeutics Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Rexgenero Ltd
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• LimFlow SA
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Micro Medical Solutions
• 公司簡介
• 公司收入
• 產品
• 最近的發展
• Cardiovascular Systems Inc.
• 公司簡介
• 公司收入
• 產品
• 最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

The global demand for Critical Limb Ischemia Treatment Market is presumed to reach the market size of nearly USD 13.27 BN by 2030 from USD 5.05 BN in 2022 with a CAGR of 11.33% under the study period 2023 - 2030.

Critical limb ischemia refers to an advanced stage of PAD (Peripheral Arterial Disease). The treatment for critical limb ischemia generally includes medications to prevent clots, reduce blood pressure and lower cholesterol, or surgery to repair or replace an artery using one of the veins or a synthetic replacement. Further, it may, at times, also include endovascular treatments. All these methods aim to restore proper blood flow to the patient's hands and feet to reduce the chances of needing an amputation.

MARKET DYNAMICS:

Major factors boosting the critical limb ischemia market include growth in the prevalence of critical limb ischemia and a rich product pipeline. Further, the adoption of promising therapeutic strategies such as optimal revascularization is also expected to augment the global critical limb ischemia treatment market. Advancements in endovascular and optimal revascularization techniques are key critical limb ischemia treatment market trends. Moreover, the need for improving the outcomes of revascularization with a focus on reducing ischemia-associated cardiovascular risk factors offers a good opportunity for the industry players.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of critical limb ischemia treatment. The growth and trends of critical limb ischemia treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the critical limb ischemia treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Treatment

• Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-Lowering Agents, Antithrombotic Agents, Others)
• Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents)

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Critical Limb Ischemia Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the critical limb ischemia treatment market include Boston Scientific Corporation, Cesca Therapeutics Inc., Abbott Laboratories, Pluristem Therapeutics Inc., Rexgenero Ltd, LimFlow SA, Micro Medical Solutions, Cardiovascular Systems Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . CRITICAL LIMB ISCHEMIA TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Treatment
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET ANALYSIS BY TREATMENT

• 6.1 Overview by Treatment
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Treatment
• 6.4 Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others) Historic and Forecast Sales by Regions
• 6.5 Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents) Historic and Forecast Sales by Regions

7 . GLOBAL CRITICAL LIMB ISCHEMIA TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE CRITICAL LIMB ISCHEMIA TREATMENT COMPANIES

• 8.1. Critical Limb Ischemia Treatment Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF CRITICAL LIMB ISCHEMIA TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Boston Scientific Corporation
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Cesca Therapeutics Inc.
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Abbott Laboratories
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Pluristem Therapeutics Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Rexgenero Ltd
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. LimFlow SA
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Micro Medical Solutions
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Cardiovascular Systems Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Treatment (USD MN)
• Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others) Market Sales by Geography (USD MN)
• Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents) Market Sales by Geography (USD MN)
• Global Critical Limb Ischemia Treatment Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Critical Limb Ischemia Treatment Report
• Market Research Process
• Market Research Methodology
• Global Critical Limb Ischemia Treatment Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Treatment
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Treatment (USD MN)
• Medication (Antiplatelet Drugs, Antihypertensive Agents, Lipid-lowering Agents, Antithrombotic Agents, Others) Market Sales by Geography (USD MN)
• Devices (Embolic Protection Devices, Peripheral Dilatation System, Balloon Dilators, Vascular Stents) Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.